Secondary stroke prevention in the era of carotid stenting

Update on recent trials

Heitham T. Hassoun, Mahmoud B. Malas, Julie A. Freischlag

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Stroke is a leading cause of morbidity and mortality worldwide. Traditional therapy for extracranial carotid artery occlusive disease, a significant risk factor for stroke, consists of optimal medical management and selective surgical treatment with carotid endarterectomy (CEA) for stroke risk reduction. Buoyed by the widespread application of percutaneous interventions for the treatment of coronary artery disease, carotid artery stenting (CAS) has steadily developed during the past decade as an alternative to CEA for patients who might benefit from surgical treatment. With greater operator experience have come advances in CAS techniques and patient selection criteria, and several single-center studies and industry-sponsored stent registries have demonstrated excellent results for CAS, especially compared with the landmark randomized CEA trials of the 1980s. Nevertheless, CAS has emerged as one of the most controversial procedures in the era of modern medicine, and recently published randomized trials from Europe have only stoked the fires of controversy. This study reviews the best available data for CAS as an alternative therapy to CEA for stroke risk reduction and gives an overview of eagerly anticipated large randomized trials.

Original languageEnglish (US)
Pages (from-to)928-935
Number of pages8
JournalArchives of Surgery
Volume145
Issue number10
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Secondary Prevention
Carotid Arteries
Carotid Endarterectomy
Stroke
Risk Reduction Behavior
Patient Selection
Modern 1601-history
Carotid Artery Diseases
Therapeutics
Complementary Therapies
Stents
Registries
Coronary Artery Disease
Industry
Morbidity
Mortality

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Secondary stroke prevention in the era of carotid stenting : Update on recent trials. / Hassoun, Heitham T.; Malas, Mahmoud B.; Freischlag, Julie A.

In: Archives of Surgery, Vol. 145, No. 10, 2010, p. 928-935.

Research output: Contribution to journalArticle

Hassoun, Heitham T. ; Malas, Mahmoud B. ; Freischlag, Julie A. / Secondary stroke prevention in the era of carotid stenting : Update on recent trials. In: Archives of Surgery. 2010 ; Vol. 145, No. 10. pp. 928-935.
@article{4f9699dddd1e49e0a7271163b1893370,
title = "Secondary stroke prevention in the era of carotid stenting: Update on recent trials",
abstract = "Stroke is a leading cause of morbidity and mortality worldwide. Traditional therapy for extracranial carotid artery occlusive disease, a significant risk factor for stroke, consists of optimal medical management and selective surgical treatment with carotid endarterectomy (CEA) for stroke risk reduction. Buoyed by the widespread application of percutaneous interventions for the treatment of coronary artery disease, carotid artery stenting (CAS) has steadily developed during the past decade as an alternative to CEA for patients who might benefit from surgical treatment. With greater operator experience have come advances in CAS techniques and patient selection criteria, and several single-center studies and industry-sponsored stent registries have demonstrated excellent results for CAS, especially compared with the landmark randomized CEA trials of the 1980s. Nevertheless, CAS has emerged as one of the most controversial procedures in the era of modern medicine, and recently published randomized trials from Europe have only stoked the fires of controversy. This study reviews the best available data for CAS as an alternative therapy to CEA for stroke risk reduction and gives an overview of eagerly anticipated large randomized trials.",
author = "Hassoun, {Heitham T.} and Malas, {Mahmoud B.} and Freischlag, {Julie A.}",
year = "2010",
doi = "10.1001/archsurg.2010.204",
language = "English (US)",
volume = "145",
pages = "928--935",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Secondary stroke prevention in the era of carotid stenting

T2 - Update on recent trials

AU - Hassoun, Heitham T.

AU - Malas, Mahmoud B.

AU - Freischlag, Julie A.

PY - 2010

Y1 - 2010

N2 - Stroke is a leading cause of morbidity and mortality worldwide. Traditional therapy for extracranial carotid artery occlusive disease, a significant risk factor for stroke, consists of optimal medical management and selective surgical treatment with carotid endarterectomy (CEA) for stroke risk reduction. Buoyed by the widespread application of percutaneous interventions for the treatment of coronary artery disease, carotid artery stenting (CAS) has steadily developed during the past decade as an alternative to CEA for patients who might benefit from surgical treatment. With greater operator experience have come advances in CAS techniques and patient selection criteria, and several single-center studies and industry-sponsored stent registries have demonstrated excellent results for CAS, especially compared with the landmark randomized CEA trials of the 1980s. Nevertheless, CAS has emerged as one of the most controversial procedures in the era of modern medicine, and recently published randomized trials from Europe have only stoked the fires of controversy. This study reviews the best available data for CAS as an alternative therapy to CEA for stroke risk reduction and gives an overview of eagerly anticipated large randomized trials.

AB - Stroke is a leading cause of morbidity and mortality worldwide. Traditional therapy for extracranial carotid artery occlusive disease, a significant risk factor for stroke, consists of optimal medical management and selective surgical treatment with carotid endarterectomy (CEA) for stroke risk reduction. Buoyed by the widespread application of percutaneous interventions for the treatment of coronary artery disease, carotid artery stenting (CAS) has steadily developed during the past decade as an alternative to CEA for patients who might benefit from surgical treatment. With greater operator experience have come advances in CAS techniques and patient selection criteria, and several single-center studies and industry-sponsored stent registries have demonstrated excellent results for CAS, especially compared with the landmark randomized CEA trials of the 1980s. Nevertheless, CAS has emerged as one of the most controversial procedures in the era of modern medicine, and recently published randomized trials from Europe have only stoked the fires of controversy. This study reviews the best available data for CAS as an alternative therapy to CEA for stroke risk reduction and gives an overview of eagerly anticipated large randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=77958550276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958550276&partnerID=8YFLogxK

U2 - 10.1001/archsurg.2010.204

DO - 10.1001/archsurg.2010.204

M3 - Article

VL - 145

SP - 928

EP - 935

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 10

ER -